Abstract: A decorative medication holder may reduce or eliminate medication non-adherence and work with standard and/or non-standard medication containers. The medication holder may include a body portion having an opening to a medication retaining cavity adapted for receiving a medication, such as a bottle of pills. The body portion also may be decorated with a kid-friendly aesthetic design, such as a character, animal, or the like to engage a child's interest. In some embodiments, the body portion may include a substantially flat outer surface. Alternatively, the body portion also may include three-dimensional limbs or the like which may be rigid or posable. In some embodiments, a cover may be provided to close the opening and/or secure the medication in the cavity. Alternatively, or additionally, the cavity may include textured lining or the like to grip the medication in the cavity. Other embodiments also are described.

Abstract: A decorative medication holder may reduce or eliminate medication non-adherence and work with standard and/or non-standard medication containers. The medication holder may include a body portion having an opening to a medication retaining cavity adapted for receiving a medication, such as a bottle of pills. The body portion also may be decorated with a kid-friendly aesthetic design, such as a character, animal, or the like to engage a child's interest. In some embodiments, the body portion may include a substantially flat outer surface. Alternatively, the body portion also may include three-dimensional limbs or the like which may be rigid or posable. In some embodiments, a cover may be provided to close the opening and/or secure the medication in the cavity. Alternatively, or additionally, the cavity may include textured lining or the like to grip the medication in the cavity. Other embodiments also are described.

Abstract: An oral solid dosage formulation is provided which contains a Factor Xa inhibitor for which oral bioavailability is not reduced by co-administration of antacids, H2 antagonists and proton pump inhibitors. Such solid dosage formulation includes the Factor Xa inhibitor of the structure, a pharmaceutically acceptable carrier, and an acid component, such as tartaric acid, whereby upon ingestion of the oral solid dosage formulation, the acid component increases solubility of the Factor Xa inhibitor in the local environment of the dissolving solid dosage formulation resulting in an otherwise lower degree of supersaturation of the Factor Xa inhibitor in such environment, than if the acid were not present. The result is that precipitation of the Factor Xa inhibitor in the form of its insoluble free base is minimized during dissolution of the Factor Xa inhibitor thereby increasing its oral bioavailability.